百奥泰公告，公司于北京时间2021年9月8日与SandozAG签署授权许可与商业化协议，将公司的 BAT1706注射液在美国、欧洲、加拿大和大部分其它BAT1706合作未覆盖的国际市场的排他的产品商业 化权益有偿许可给Sandoz。首付款及里程碑款总金额最高至1.55亿美元，其中包括2,750万美元首付款、 累计不超过1.275亿美元里程碑付款和两位数百分比的利润分成。根据协议约定，公司于近日收到 Sandoz支付的450.00万美元里程碑付款。 来源：滚动播报 ...

百奥泰生物制药股份有限公司关于公司2026年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次日常关联交易预计事项无需提交股东会审议 ● 百奥泰生物制药股份有限公司（以下简称"公司"或"百奥泰"）本次日常关联交易是公司及子公司正常 生产经营所必需，定价公允、结算时间与方式合理，不存在损害公司及中小股东利益的情况，不会对关 联方形成依赖，不影响公司的独立性。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于2025年12月29日召开第三届董事会第五次会议审议通过了《关于公司2026年度日常关联交易预计 的议案》，关联董事HUANG XIANMING（黄贤明）回避表决，其余非关联董事一致审议通过该议 案。审议程序符合《中华人民共和国公司法》《中华人民共和国证券法》等法律法规以及《百奥泰生物 制药股份有限公司章程》的有关规定。 公司于2025年12月29日召开第三届董事会独立董事第一次专门会议审议通过了《关于公司2026年度日常 关联交易预计的议案》，公司独立董事 ...

证券代码：688177 证券简称：百奥泰 公告编号：2025-072 百奥泰生物制药股份有限公司 关于公司2026年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次日常关联交易预计事项无需提交股东会审议 百奥泰生物制药股份有限公司（以下简称"公司"或"百奥泰"）本次日常 关联交易是公司及子公司正常生产经营所必需，定价公允、结算时间与方式合理， 不存在损害公司及中小股东利益的情况，不会对关联方形成依赖，不影响公司的 独立性。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于 2025 年 12 月 29 日召开第三届董事会第五次会议审议通过了《关于 公司 2026 年度日常关联交易预计的议案》，关联董事HUANG XIANMING（黄 贤明）回避表决，其余非关联董事一致审议通过该议案。审议程序符合《中华人 民共和国公司法》《中华人民共和国证券法》等法律法规以及《百奥泰生物制药 股份有限公司章程》的有关规定。 公司于 2025 年 12 月 29 日召开第三届董事 ...

Group 1 - The biopharmaceutical sector increased by 0.18% on December 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] - Key stocks in the biopharmaceutical sector showed various performance, with Jindike (688670) rising by 4.66% to a closing price of 22.45 [1] Group 2 - The biopharmaceutical sector experienced a net outflow of 307 million yuan from institutional investors, while retail investors saw a net inflow of 359 million yuan [2] - Notable declines included Te Bao Biological (688278), which fell by 3.14% to a closing price of 80.90 [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Wan Ze Co. (000534) achieving a turnover of 488 million yuan [1][2] Group 3 - Jindike (688670) had a net inflow of 25.23 million yuan from institutional investors, while retail investors had a net outflow of 23.95 million yuan [3] - Other stocks like Zhi Xiang Jin Tai (688443) and Shen Zhou Cell (688520) also showed mixed net inflows and outflows from different investor categories [3] - The overall trend indicates a divergence in investor sentiment, with institutional investors pulling back while retail investors increased their positions [2][3]

数据显示，鹏华基金旗下1只基金重仓百奥泰。鹏华安泽混合A（009096）三季度持有股数600股，占基 金净值比例为0.02%，位居第十大重仓股。根据测算，今日浮盈赚取约708元。 12月23日，百奥泰涨5.09%，截至发稿，报24.34元/股，成交3410.28万元，换手率0.35%，总市值100.79 亿元。 资料显示，百奥泰生物制药股份有限公司位于广东省广州市国际生物岛螺旋二路18号，成立日期2003年 7月28日，上市日期2020年2月21日，公司主营业务涉及从事创新药和生物类似药的研发、生产业务。主 营业务收入构成为：药品销售业务91.90%，授权许可业务6.55%，代加工业务0.90%，技术服务业务 0.65%。 从基金十大重仓股角度 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 鹏华安泽混合A（009096）成立日期2020年3月25日，最新规模1330.6万。今年以来收益2.56%，同类排 名7347/8088；近一年收益2.57%，同类排名7290/80 ...

Group 1 - The core viewpoint of the news is that Baiotai's stock has shown a mixed performance in recent months, with a year-to-date increase of 21.93% but a decline of 21.13% over the past 60 days [2] - As of December 23, Baiotai's stock price was 23.63 yuan per share, with a market capitalization of 9.785 billion yuan and a trading volume of 816.40 million yuan [1] - The company has seen a net inflow of 794,500 yuan from major funds, with significant buying activity accounting for 15.09% of total trading [1] Group 2 - Baiotai's main business revenue composition includes 91.90% from drug sales, 6.55% from licensing, 0.90% from contract manufacturing, and 0.65% from technical services [2] - For the period from January to September 2025, Baiotai achieved an operating income of 684 million yuan, representing a year-on-year growth of 17.57%, while the net profit attributable to the parent company was -224 million yuan, reflecting a 38.72% increase [2] - As of September 30, 2025, the number of shareholders in Baiotai was 9,397, a decrease of 0.89% from the previous period, with an average of 44,065 circulating shares per person, an increase of 0.89% [2]

Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 百奥泰生物制药股份有限公司董事会 一、获取补助的基本情况 百奥泰生物制药股份有限公司（以下简称"公司"）近日收到两笔与收益 相关的政府补助款项共计人民币 2,900.00 万元。 二、补助的类型及其对上市公司的影响 公司根据《企业会计准则第 16 号——政府补助》等相关规定，确认上述事 项并划分补助的类型为与收益相关的政府补助，预计将对公司 2025 年度损益产 生一定的积极影响。 证券代码：688177 证券简称：百奥泰 公告编号：2025-071 上述政府补助未经审计，具体的会计处理以及对公司损益的影响最终以审 计机构年度审计确认后的结果为准。敬请广大投资者注意投资风险。 百奥泰生物制药股份有限公司 关于获得政府补助的公告 特此公告。 2025 年 12 月 23 日 ...

百奥泰12月22日公告，公司近日收到两笔与收益相关的政府补助款项共计人民币2900万元。上述政府补 助未经审计，具体的会计处理以及对公司损益的影响最终以审计机构年度审计确认后的结果为准。 ...

百奥泰公告称，近日收到两笔与收益相关的政府补助款项，共计2900万元。公司依据相关会计准则，将 其确认为与收益相关的政府补助，预计对2025年度损益产生一定积极影响。不过，该补助未经审计，具 体会计处理和对损益的影响以审计机构年度审计确认结果为准。 ...